Symbol | Exchange | Currency |
|---|
DEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Oil & Gas, Technology and Healthcare sectors propelled shares higher. At the close in NYSE, the...
Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Utilities, Technology and Financials sectors propelled shares higher while losses in the...
DEVON, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies...
. Oral Presentation Details Title:An Open-Label, Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Zynerba Pharmaceuticals, Inc. is primarily engaged in the pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The Company is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. It has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
| Average | 7.000 (+713.95% Upside) |
| High | 11 |
| Low | 1 |
| Price | 0.86 |
| No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Sell |
| Technical Indicators | Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.0425 | 0.045 | 0.04 | +0.0025 | +6.25% | 58.51K | Toronto | |||
| 14.00 | 14.00 | 13.75 | +0.20 | +1.45% | 900.00 | Toronto | |||
| 85.45 | 85.94 | 83.20 | +1.05 | +1.24% | 3.26M | Toronto | |||
| 46.74 | 47.22 | 43.57 | +2.74 | +6.23% | 32.30K | Toronto | |||
| 0.015 | 0.015 | 0.015 | -0.0250 | -62.50% | 1.43K | CSE | |||
| 0.04 | 0.04 | 0.04 | -0.005 | -11.11% | 217.33K | TSXV | |||
| 12.44 | 12.44 | 12.25 | +0.39 | +3.24% | 4.15K | Toronto | |||
| 38.85 | 39.06 | 37.70 | +0.85 | +2.24% | 2.56K | Toronto | |||
| 0.12 | 0.12 | 0.11 | +0.02 | +20.00% | 495.31K | CSE | |||
| 9.32 | 9.37 | 8.79 | +0.53 | +6.03% | 258.16K | Toronto | |||
| 57.41 | 57.77 | 56.81 | +0.13 | +0.23% | 739.75K | Toronto | |||
| 1.12 | 1.12 | 1.12 | 0.00 | 0.00% | 2.20K | Toronto | |||
| 2.08 | 2.08 | 1.97 | +0.05 | +2.46% | 185.62K | TSXV | |||
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 0.00 | CSE | |||
| 9.89 | 9.96 | 9.26 | +0.82 | +9.04% | 58.99K | NEO |